Special issue of Neurology Research Review, focusing specifically on MS.
In this issue, an NZ report finds a potential missed opportunity to decrease the cost of MS treatment, a US survey evaluates risk tolerance associated with current MS therapies, and Italian investigators review outcomes after AHSCT following natalizumab discontinuation in patients with aggressive MS. A subgroup analysis of the OPERA I and II studies reports that the efficacy benefits of ocrelizumab over interferon beta-1a in RRMS are maintained across different demographic, treatment and MS-related subgroups and an Italian cohort study gives insight into the
longitudinal course of natalizumab-related PML.
Neurology Research Review MS Supplement Issue 57 2019
Article courtesy of Dr Jennifer Pereira email@example.com